Sana Biotechnology, Inc.
A developer of engineered cell therapies, Sana Biotechnology works to repair or replace damaged cells in the body using its "hypoimmune" technology, which masks cells so a patient's immune system won't reject them. Founded in 2018 by former leaders of the CAR T-cell pioneer Juno Therapeutics, the company takes its name from the Latin word "sana," meaning healthy or sound. Its lead programs are off-the-shelf CAR T-cell therapies in development for autoimmune diseases like lupus.
Bought 1.82M
Bought 1.82M
Bought 1.82M
Granted 141.7K
Granted 83.5K
Sold 290.9K
Sold 300.0K
Sold 75.0K
Granted 55.9K
Granted 125.0K
Sold 25.0K
Granted 11.0K
Granted 3.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Nelsen RobertDirector, 10% owner · 3 transactions | — | 35.21Mas of Feb 2024 | — | 1.82M | — |
| Bybee Clinton +3 co-filers10% owner · 3 transactions | — | 35.19Mas of Feb 2024 | — | 1.82M | — |
| Afeyan Noubar +8 co-filers10% owner · 6 transactions | — | 25.58Mas of Sep 2023 | — | — | — |
| ARCH Venture Fund IX Overage, L.P. +9 co-filers10% owner · 3 transactions | — | 22.75Mas of Feb 2024 | — | 1.82M | — |
| Harr StevePresident & CEO, Director · 6 transactions | — | 8.96M | 141.7K | — | — |
| Bishop Hans EdgarDirector · 11 transactions | +1.4% | 5.85M | 83.5K | — | — |
| FMR LLC10% owner, See Remark 1 · 4 transactions | — | 4.71Mas of Jan 2025 | — | — | 290.9K |
| Mulligan RichardDirector · 2 transactions | -10% | 2.70Mas of Sep 2024 | — | — | 300.0K |
| Hordo ChristianEVP, Chief Business Officer · 1 transaction | -8% | 867.5Kas of Dec 2023 | — | — | 75.0K |
| Wyrick Susan D.See Remarks · 20 transactions | — | 197.2K | 55.9K | — | — |
| Patel Dhavalkumar DhirajlalEVP, Chief Scientific Officer · 2 transactions | — | 183.4K | 125.0K | — | — |
| Yang Patrick YDirector · 1 transaction | -14.3% | 149.3Kas of Mar 2024 | — | — | 25.0K |
| Cassidy Bernard JEVP & General Counsel · 2 transactions | +21.8% | 113.0Kas of Mar 2025 | 11.0K | — | — |
| Wilderotter Mary AgnesDirector · 2 transactions | +99.7% | 7.1Kas of Jan 2024 | 3.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +4.76M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.